had active SLE disease and have been on stable SLE treatment regimen. Lupus activity was defined by presence of SS score of at least 4. Some of the exclusions were patients treated with ...

Background A 23-year-old white woman with a 3-year history of systemic lupus erythematosus and a 15 ... the possibility of metabolic abnormalities (Table 1). The results of an analysis of ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus ... May 23, 2024 — Treatment of autoimmune diseases ...

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common ... risk and support the successful discontinuation of GCs in individuals with systemic lupus erythematosus (SLE). In ...

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...